

1-(α -Boc-aminoacyl)benzotriazoles: stable chiral α -aminoacylation reagents

Alan R. Katritzky,* Mingyi Wang, Hongfang Yang, Suoming Zhang,[§]
and Novruz G. Akhmedov

Center for Heterocyclic Compounds, Department of Chemistry,
University of Florida, Gainesville, Florida 32611-7200

E-mail: katritzky@chem.ufl.edu

Submitted in honor of the 65th anniversary of Albert Padwa as a token of many years of
friendship

(received 03 Aug 02; accepted 04 Sep 02; published on the web 12 Sep 02)

Abstract

The chiral α -*N*-(tert-butoxycarbonyl)aminoacylbenzotriazoles [(*N*-Boc-aminoacyl)-benzotriazoles] **3a–e** are stable crystalline intermediates, easily prepared (61–88%) from *N*-Boc- α -amino acids **1a–e**. Compounds **3a–e** react with achiral or chiral amines at 0–20 °C to give α -(*N*-Boc-amino)amides with no detectable racemization.


Keywords: α -(*N*-Boc-aminoacyl)benzotriazoles, α -aminoacylation

Introduction

Amide bond formation between amino-acid components is a main goal in the synthesis of many organic compounds of biological interest such as peptides, peptoids, oligocarbamates, oligoamides, β -lactams, polyenamides, benzodiazepines, diketopiperazines, and hydantoins. Contemporary protocols for the preparation of *N*-protected α -acylamino amides involve the formation of intermediate active esters. Many peptide coupling reagents¹ have essentially eliminated racemization of the amino acid component and the undesired side reactions² which can arise in direct synthesis of primary, secondary, and tertiary amides from acids or their classical activated derivatives (acyl halides, acid anhydrides, mixed anhydrides, or esters) with ammonia or amines. However, stable, crystalline chiral α -aminoacylation reagents have rarely been documented. Recent efforts to obtain easily isolated and stored active esters have linked modern activating groups (e.g., HOBt, HOAt, HOSu and PFP) to solid supports.³ Recently, stable *N*-hydroxysuccinimide (HOSu) - derived active esters have been obtained crystalline.⁴

N-Protected amino acid chlorides have long been known,⁵ their most successful application to peptide synthesis involved Fmoc-amino acids.⁶ Most *N*-protected amino acid chlorides proved not to be generally storable because of their high reactivity and sensitivity to cause degradation,⁷ decomposition and racemization² on storage. *N*-Protected amino acid fluorides are more stable than the corresponding chlorides toward neutral oxygen nucleophiles such as water and methanol, yet are of high reactivity toward anionic nucleophiles and amines. Acid fluorides display considerable advantages in peptide synthesis;^{7,8} however, racemization was observed upon pretreatment of BOC-Phe-F with triethylamine in methylene chloride,⁷ low temperature is required for storage, especially in the *t*-BOC series⁷ and a large excess of acid fluorides was needed in the coupling step.^{8b}

Acylbenzotriazoles have long been known as neutral acylating reagents.⁹ More recent work has included simple methods for their preparation and their application to prepare primary, secondary and tertiary amides¹⁰ and cinnamoyl hydrazides.¹¹ We now extend the acylbenzotriazole chemistry to prepare stable *N*-Boc- α -amino acylbenzotriazoles derived from *N*-Boc- α -amino acids and their utilization in the synthesis of chiral α -(*N*-protected amino)acid amides (Scheme 1).



Scheme 1

Results and Discussion

Preparation of (*N*-Boc- α -aminoacyl)benzotriazoles **3a–e**


As shown in Scheme 1, the (*N*-Boc- α -aminoacyl)benzotriazoles **3a–e** were prepared in 61–88% yields from commercially available *N*-protected α -amino acids **1a–e** and BtSO₂Me (**2**).¹⁰ Compounds **3a–e** are colorless solids and crystallized from hexane–ethyl acetate; **3a–e** showed no detectable change on storage at 20 °C for 6 months. The ¹³C NMR spectra of **3a–e** displayed the expected signals characteristic of acylbenzotriazoles at δ ca. 131 (d), 127 (d), 120 (d), and 114 (d), and of the carbonyl carbons of the amide and carbamate groups at δ ca. 173 (s) and 155 (s), respectively.

Preparation of *N*-(acylamino)amides **4a,b**, **5a–e**, **6a–e**

Reactions of (*N*-Boc- α -aminoacyl)benzotriazoles **3a** and **3b** with amines in THF at room temperature afforded amides **4a** and **4b** in 82–87% yields (Table 1, Scheme 2). These yields and

the procedure are comparable with those previously reported for the preparation of simple amides from RCOBt and amines (e.g., *N*-(4-methoxyphenyl)-2-pyridinecarboxamide, 83%).¹⁰

The most reliable technique for the determination of enantiomer composition is by the NMR analysis of covalent diastereomer mixtures,¹² as exemplified by the preparation of derivatives of chiral alcohols or amines from optically active acids. α -Methylbenzylamides of *N*-protected amino acids have frequently served as model compounds for studies of optical purity and stability towards racemization.¹³ With this in mind, (*S*)-(-)- α -methylbenzylamine **7** and its antipode (*R*)-(+)- α -methylbenzylamine **8** were converted into the corresponding diastereomeric modified amides **5a–e** and **6a–e**, respectively, in isolated yields of 85–99% (average 93%) by reactions with **3a–e** at 0–20 °C.



For designation of R in **5a–e** and **6a–e**, see Scheme 1 and Table 1

Scheme 2

The diastereomeric excess (*de*) values for compounds **5a–e** and **6a–e** were determined as 93–99% by ¹H NMR analysis of the amides after column chromatographic purification (Table 1). For compounds **5a–d** and **6a–d**, the resonances for the terminal methyl of the amino acid portion of the molecules were separated by 0.01–0.05 ppm (Figure 1). For compounds **5e** and **6e**, the α -methyl proton resonances were separated enough to allow determination of the diastereomeric ratio (Figure 2). The *de* values of **5a–e** and **6a–e** are summarized in Table 1. This indicated that the α -aminoacylations occurred with complete retention of the chirality of both the precursors in the products. Optical rotations were also examined for compound **4a**, which had a rotation of $[\alpha]_D^{20}$, -52°, that reported¹⁴ is -61.2°. The measured $[\alpha]_D^{20}$ of **4b** is -5.5°, that reported¹⁵ is +9.2°. Problems with the measurement of the optical rotation for the determination of enantiomeric purity of optically active compounds have been discussed.¹²

One-pot reaction has also been investigated for **4b**, **5e** and **6e**. After the formation of the (*N*-Boc- α -aminoacyl)benzotriazoles **3a–e** were completed, amines were added *in situ* to the reaction mixture at room temperature and stirred for an appropriate time to provide **4b**, **5e** and **6e** in very

good one-pot yields. In cases **5e** and **6e**, one-pot reaction gave the same de values as the above method. This success in the one-pot procedure should encourage the application of (*N*-Boc- α -aminoacyl)benzotriazoles in the formation of the amide bond.




Figure 1. ^1H NMR spectra of compounds **5e** and **6e** in CDCl_3 (aliphatic region).




Figure 2. ^1H NMR spectra of compounds **5d** and **6d** in CDCl_3 (aliphatic region).

Table 1. *N*-(Acylamino)amides **4a,b**, **5a–e**, **6a–e**

| Entry | R | $[\alpha]_{20}$ | Mp ($^{\circ}\text{C}$) | De (%) | Yield (%) |
|-------|--------------------------------|-----------------|---------------------------|--------|-----------------------|
| 4a | CH_3 | -52 | 174 | - | 82 |
| 4b | $(\text{CH}_3)_2\text{CH}$ | -5.5 | oil | - | 87 (82 ^a) |
| 5a | CH_3 | - | 119.0–119.5 | 99 | 91 |
| 5b | $(\text{CH}_3)_2\text{CH}$ | - | 142–143 | 96 | 93 |
| 5c | CH_3CH_2 | - | 109–110 | 93 | 93 |
| 5d | $(\text{CH}_3)_2\text{CHCH}_2$ | - | 143–143.5 | 99 | 85 |
| 5e | PhCH_2 | - | 131–132 | 99 | 96 (80) |
| 6a | CH_3 | - | 91.5–92.5 | 99 | 99 |
| 6b | $(\text{CH}_3)_2\text{CH}$ | - | 128–128 | 99 | 89 |
| 6c | CH_3CH_2 | - | 93–94 | 99 | 90 |
| 6d | $(\text{CH}_3)_2\text{CHCH}_2$ | - | 137–138 | 99 | 95 |
| 6e | PhCH_2 | - | 127–128 | 99 | 95 (77) |

^a Yields in parentheses are for the one-pot procedure.

In conclusion, we have described a methodology for the preparation and synthetic utilization of (*N*-Boc- α -aminoacyl)benzotriazoles **3a–e** via *N*-methanesulfonylbenzotriazole **2**. The excellent stability of the isolated (*N*-Boc- α -aminoacyl)benzotriazoles **3a–e** may provide broad applicability. The simplicity, operational ease and lack of racemization offer advantages over

conventional coupling techniques and could make this methodology a method of choice for the preparation of amides and peptides using solid phase combinatorial techniques where crystalline, stable reagents have obvious advantages.

Experimental Section

General Procedures. Melting points were determined on a capillary melting point apparatus equipped with a digital thermometer. NMR spectra were recorded in CDCl₃ with tetramethylsilane as the internal standard for ¹H (300 MHz) and the solvent for ¹³C (75 MHz) NMR. THF was distilled from sodium/benzophenone under nitrogen immediately prior to use. All reactions with air-sensitive compounds were carried out under argon atmosphere. Column chromatography was conducted using silica gel (230–400 mesh) and ethyl acetate–hexane.

General procedure for the preparation of 3a–e

To a solution of *N*-protected amino acid (10 mmol) in THF (50 mL), BtMs (11 mmol) and Et₃N (11 mmol) were added at room temperature. The reaction mixture was heated and refluxed 6–12 h. The solvent was removed *in vacuo* to dryness. The residue was dissolved in ethyl acetate and washed sequentially with sat. citric acid, sat. Na₂CO₃ and H₂O, and dried over MgSO₄. Concentration under reduced pressure gave desired product, which can be recrystallized from hexane–ethyl acetate.

***L*-tert-Butyl-*N*-[2-(1*H*-1,2,3-benzotriazol-1-yl)-1-methyl-2-oxoethyl]carbamate (3a).** Colorless prisms (61%), mp 68–69 °C, $[\alpha]_D^{20}$ –17.7° (CHCl₃); ¹H NMR δ 8.27 (d, *J* = 8.1 Hz, 1H), 8.13 (d, *J* = 8.2 Hz, 1H), 7.67 (dd, *J* = 7.5, 7.6 Hz, 1H), 7.52 (dd, *J* = 7.5, 7.6 Hz, 1H), 5.74 (m, 1H), 5.32 (d, *J* = 5.9 Hz, 1H), 1.65 (d, *J* = 7.3 Hz, 3H), 1.45 (s, 9H); ¹³C NMR δ 173.2, 155.5, 146.4, 131.6, 131.1, 126.9, 120.7, 114.8, 80.8, 50.6, 28.7, 19.4. Anal. Calcd for C₁₄H₁₈N₄O₃: C, 57.92; H, 6.25; N, 19.30. Found: C, 58.06; H, 6.44; N, 19.30.

***L*-tert-Butyl-*N*-[1-(1*H*-1,2,3-benzotriazol-1-ylcarbonyl)-2-methylpropyl]carbamate (3b).** Colorless needles (83%), mp 120–121 °C, $[\alpha]_D^{20}$: –47.5° (CH₃OH); ¹H NMR δ 8.28 (d, *J* = 8.1 Hz, 1H), 8.14 (d, *J* = 8.2 Hz, 1H), 7.68 (dd, *J* = 7.4, 7.3 Hz, 1H), 7.54 (dd, *J* = 7.4, 7.5 Hz, 1H), 5.70–5.66 (m, 1H), 5.33 (d, *J* = 8.4 Hz, 1H), 2.47–2.17 (m, 1H), 1.46 (s, 9H), 1.11 (d, *J* = 6.7 Hz, 3H), 0.97 (d, *J* = 6.7 Hz, 3H); ¹³C NMR δ 171.9, 155.6, 145.9, 130.9, 130.5, 126.3, 120.2, 114.3, 80.1, 58.9, 31.4, 28.2, 19.6, 16.9. Anal. Calcd for C₁₆H₂₂N₄O₃: C, 60.36; H, 6.96; N, 17.60. Found: C, 60.56; H, 7.13; N, 17.72.

***L*-tert-Butyl-*N*-[1-(1*H*-1,2,3-benzotriazol-1-ylcarbonyl)propyl]carbamate (3c).** Colorless needles (78%), mp 85–86 °C, $[\alpha]_D^{20}$: –45.0° (CHCl₃); ¹H NMR δ 8.29 (d, *J* = 8.1 Hz, 1H), 8.15 (d, *J* = 8.1 Hz, 1H), 7.68 (dd, *J* = 7.5, 7.8 Hz, 1H), 7.54 (dd, *J* = 7.5, 7.8 Hz, 1H), 5.75–5.61 (m, 1H), 5.31 (brd, *J* = 7.2 Hz, 1H), 2.25–2.06 (m, 1H), 1.98–1.82 (m, 1H), 1.46 (s, 9H), 1.08 (t, *J* = 7.5, 7.5 Hz, 3H); ¹³C NMR δ 172.1, 155.4, 145.8, 131.0, 130.5, 126.3, 120.1, 114.2, 80.1, 55.2,

28.2, 26.2, 9.9. Anal. Calcd for C₁₅H₂₀N₄O₃: C, 59.20; H, 6.62; N, 18.41. Found: C, 59.52; H, 7.08; N, 18.60.

L-tert-Butyl-N-[1-(1*H*-1,2,3-benzotriazol-1-yl)carbonyl]-3-methylbutyl]carbamate (3d). Colorless needles (66%), mp 134–136 °C, $[\alpha]_D^{20}$: -4.0° (CHCl₃); ¹H NMR δ 8.27 (d, *J* = 8.1 Hz, 1H), 8.13 (d, *J* = 8.1 Hz, 1H), 7.67 (dd, *J* = 7.8, 7.3 Hz, 1H), 7.53 (dd, *J* = 7.7, 7.6 Hz, 1H), 5.80–5.74 (m, 1H), 5.23 (brs, 1H), 1.88–1.80 (m, 2H), 1.74–1.64 (m, 1H), 1.45 (s, 9H), 1.10 (d, *J* = 5.6 Hz, 3H), 0.98 (d, *J* = 6.0 Hz, 3H); ¹³C NMR δ 172.9, 155.5, 146.0, 131.2, 130.6, 126.4, 120.3, 114.4, 80.3, 53.1, 41.9, 28.3, 25.3, 23.2, 21.3. Anal. Calcd for C₁₇H₂₄N₄O₃: C, 61.43; H, 7.28; N, 16.85. Found: C, 61.74; H, 7.10; N, 17.00.

L-tert-Butyl-N-[2-(1*H*-1,2,3-benzotriazol-1-yl)-1-benzyl-2-oxoethyl]carbamate (3e). Colorless needles (81%), mp 144–145 °C; ¹H NMR δ 8.26 (d, *J* = 7.8 Hz, 1H), 8.17 (d, *J* = 8.1 Hz, 1H), 8.14 (dd, *J* = 5.9, 2.4 Hz, 1H), 7.68 (dd, *J* = 7.4, 7.7 Hz, 1H), 7.57–7.16 (m, 6H), 6.05–5.95 (m, 1H), 3.46 (dd, *J* = 4.5, 13.5 Hz, 1H), 3.19 (dd, *J* = 7.4, 13.9 Hz, 1H), 1.41 (s, 9H); ¹³C NMR δ 171.3, 155.1, 146.0, 135.2, 131.0, 130.7, 129.2, 128.6, 127.2, 126.4, 120.3, 114.3, 80.3, 55.2, 38.8, 28.2. Anal. Calcd for C₂₀H₂₂N₄O₃: C, 65.56; H, 6.05; N, 15.29. Found: C, 65.68; H, 6.38; N, 14.90.

General procedure for the preparation of 4a,b, 5a–e, 6a–e

To a solution of the *N*-(*N*-Boc- α -aminoacyl)benzotriazole **3a–e** (5 mmol) in dry THF (30 mL), a solution of the corresponding amines (5 mmol) in THF (2 mL) was added at 0 °C over 5 min. The reaction mixture was stirred at 0–20 °C overnight. The solvent was removed *in vacuo* and the residue was purified by column chromatography to give the desired products, which can be recrystallized from hexane–ethyl acetate.

[1-(*N-tert-Butyloxycarbonyl*)amino-1-methyl]-*N*-phenylacetamide (4a). Colorless needles (82%), mp 174 °C (lit.¹⁴ 175 °C), $[\alpha]_D^{20}$: -52° (lit.¹⁴ -61.2°); ¹H NMR δ 8.44 (br s, 1H), 7.52 (d, *J* = 7.9 Hz, 2H), 7.31 (t, *J* = 7.6 Hz, 2H), 7.10 (t, *J* = 7.3 Hz, 1H), 5.06 (br s, 1H), 4.32 (m, 1H), 1.47 (s, 9H), 1.43 (d, *J* = 7.3 Hz, 3H); ¹³C NMR δ 171.1, 156.1, 137.8, 128.9, 124.2, 119.8, 80.5, 50.7, 28.3, 17.8.

[2-Methyl-1-(pyrrolidine-1-carbonyl)propyl]carbamic acid *tert*-butyl ester (4b). Colorless oil (87%), $[\alpha]_D^{20}$: -5.5° (lit.¹⁵ +9.2°). ¹H NMR δ 5.31 (d, *J* = 9.0 Hz, 1H), 4.20–4.15 (m, 1H), 3.63–3.57 (m, 1H), 3.47–3.32 (m, 3H), 1.91–1.76 (m, 5H), 1.35 (s, 9H), 0.89 (d, *J* = 6.7 Hz, 3H), 0.85 (d, *J* = 6.7 Hz, 3H); ¹³C NMR δ 170.2, 155.4, 78.7, 56.6, 46.2, 45.3, 30.9, 27.9, 25.6, 23.8, 19.1, 17.1.

tert-Butyl N-((1*S*)-1-methyl-2-oxo-2-[(1*S*)-1-phenylethyl]amino)ethyl]carbamate (5a). Colorless needles (91%), mp 119–120 °C; ¹H NMR δ 7.35–7.22 (m, 5H), 6.62 (brs, 1H), 5.14–5.04 (m, 2H), 4.16 (brs, 1H), 1.47 (d, *J* = 7.0 Hz, 3H), 1.43 (s, 9H), 1.33 (d, *J* = 7.0 Hz, 3H); ¹³C NMR δ 171.7, 155.6, 143.0, 128.6, 127.3, 126.0, 80.1, 50.1, 48.6, 28.2, 21.8, 18.0. Anal. Calcd for C₁₆H₂₄N₂O₃: C, 65.73; H, 8.27; N, 9.58. Found: C, 65.66; H, 8.38; N, 9.60.

tert-Butyl N-[(1S)-2-methyl-1-([(1S)-1-phenylethyl]amino)carbonylpropyl]carbamate (5b). Colorless macrocrystals (93%), mp 142–143 °C; ¹H NMR δ 7.41–7.28 (m, 5H), 6.34 (brd, *J* = 7.4 Hz, 1H), 5.25–5.10 (m, 2H), 3.93–3.88 (m, 1H), 2.20–2.05 (m, 1H), 1.53 (d, *J* = 6.9 Hz, 3H), 1.48 (s, 9H), 0.96–0.92 (m, 6H); ¹³C NMR δ 170.9, 156.0, 143.1, 128.5, 127.1, 126.0, 79.6, 60.0, 48.6, 30.8, 28.2, 21.7, 19.2, 17.9. Anal. Calcd for C₁₈H₂₈N₂O₃: C, 67.47; H, 8.81; N, 8.74. Found: C, 67.71; H, 9.10; N, 8.73.

tert-Butyl N-[(1S)-1-([(1S)-1-phenylethyl]amino)carbonylpropyl]carbamate (5c). Colorless needles (93%), mp 109–110 °C (lit.¹⁶ no melting point given); ¹H NMR δ 7.36–7.23 (m, 5H), 6.38 (brs, 1H), 5.16–5.00 (m, 2H), 4.02–3.92 (m, 1H), 1.91–1.76 (m, 1H), 1.66–1.56 (m, 1H), 1.48 (d, *J* = 6.9 Hz, 3H), 1.43 (s, 9H), 0.90 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (DMSO-*d*₆) δ 171.1, 155.3, 144.7, 128.2, 126.6, 125.8, 77.9, 55.6, 47.7, 28.2, 25.4, 22.5, 10.3.

tert-Butyl N-[(1S)-3-methyl-1-([(1S)-1-phenylethyl]aminocarbonylbutyl]carbamate (5d). Colorless needles (85%), mp 142–143 °C; ¹H NMR δ 7.37–7.22 (m, 5H), 6.45 (brd, *J* = 7.1 Hz, 1H), 5.12–5.05 (m, 1H), 4.89 (brs, 1H), 4.06 (brs, 1H), 1.67–1.53 (brs, 2H), 1.51–1.43 (m, 1H), 1.47 (d, *J* = 6.9 Hz, 3H), 1.43 (s, 9H), 0.91 (d, *J* = 5.9 Hz, 3H), 0.90 (d, *J* = 6.0 Hz, 3H); ¹³C NMR δ 171.7, 155.8, 143.2, 128.5, 127.2, 126.0, 79.9, 53.1, 48.6, 41.1, 28.3, 24.7, 22.9, 21.8. Anal. Calcd for C₁₉H₃₀N₂O₃: C, 68.23; H, 9.04; N, 8.38. Found: C, 68.38; H, 9.25; N, 8.41.

tert-Butyl N-[(1S)-1-benzyl-2-oxo-2-([(1S)-1-phenylethyl]amino)ethyl]carbamate (5e). Colorless needles (96%), mp 131–132 °C (lit.¹³ 138–139 °C); ¹H NMR δ 7.30–7.08 (m, 10H), 6.07 (d, *J* = 8.0 Hz, 1H), 5.12 (brs, 1H), 5.07–5.00 (m, 1H), 4.32–4.22 (m, 1H), 3.07 (dd, *J* = 6.4, 13.6 Hz, 1H), 2.99 (dd, *J* = 7.7, 13.3 Hz, 1H), 1.41 (d, *J* = 6.7 Hz, 3H), 1.40 (s, 9H); ¹³C NMR δ 170.2, 155.4, 142.6, 136.6, 129.3, 128.6, 128.5, 127.2, 126.8, 126.0, 80.1, 55.9, 48.6, 38.5, 28.2, 21.5. Anal. Calcd for C₂₂H₂₈N₂O₃: C, 71.71; H, 7.66; N, 7.60. Found: C, 71.48; H, 7.88; N, 7.57.

tert-Butyl N-[(1S)-1-methyl-2-oxo-2-[(1R)-1-phenylethyl]aminoethyl]carbamate (6a). Colorless needles (99%), mp 91.5–93.0 °C; ¹H NMR δ 7.34–7.21 (m, 5H), 6.60 (brs, 1H), 5.12–5.03 (m, 1H), 4.94 (brs, 1H), 4.15–4.10 (m, 1H), 1.48 (d, *J* = 6.9 Hz, 3H), 1.42 (s, 9H), 1.34 (d, *J* = 7.0 Hz, 3H); ¹³C NMR δ 171.4, 155.6, 143.1, 128.6, 127.2, 125.9, 80.1, 49.9, 48.7, 28.2, 22.0, 17.6. Anal. Calcd for C₁₆H₂₄N₂O₃: C, 65.73; H, 8.27; N, 9.58. Found: C, 65.70; H, 8.61; N, 9.62.

tert-Butyl N-[(1S)-2-methyl-1-([(1R)-1-phenylethyl]amino)carbonylpropyl]carbamate (6b). Colorless macrocrystals (89%), mp 127–128 °C; ¹H NMR δ 7.34–7.22 (m, 5H), 6.28 (brd, *J* = 6.7 Hz, 1H), 5.13–5.06 (m, 2H), 3.88–3.82 (m, 1H), 2.19–2.08 (m, 1H), 1.48 (d, *J* = 7.0 Hz, 3H), 1.43 (s, 9H), 0.96 (d, *J* = 6.7 Hz, 3H), 0.91 (d, *J* = 6.3 Hz, 3H); ¹³C NMR δ 170.7, 155.9, 142.9, 128.5, 127.2, 126.0, 79.7, 60.2, 48.7, 30.5, 28.2, 21.9, 19.3, 18.0. Anal. Calcd for C₁₈H₂₈N₂O₃: C, 67.47; H, 8.81; N, 8.74. Found: C, 67.67; H, 9.04; N, 8.61

tert-Butyl N-[(1R)-1-([(1R)-1-phenylethyl]amino)carbonylpropyl]carbamate (6c). Colorless needles (90%), mp 93–94 °C (lit.¹⁶ no melting point given); ¹H NMR δ 7.34–7.23 (m, 5H), 6.40 (m, 1H), 5.15–5.05 (m, 1H), 4.96 (brs, 1H), 4.05–3.85 (m, 1H), 1.95–1.80 (m, 1H), 1.81–1.54 (m, 1H), 1.48 (d, *J* = 7.0 Hz, 3H), 1.43 (s, 9H), 0.95 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (DMSO-*d*₆) δ 171.1, 155.3, 144.4, 128.1, 126.5, 126.0, 77.9, 55.6, 47.7, 28.2, 25.2, 22.5, 10.4.

tert-Butyl N-[(1S)-3-methyl-1-[(1R)-1-phenylethyl]aminocarbonyl]butyl]carbamate (6d). Colorless needles (95%), mp 137–138 °C; ¹H NMR δ 7.35–7.23 (m, 5H), 6.56 (brs, 1H), 5.11–5.06 (m, 1H), 4.86 (d, *J* = 8.2 Hz, 1H), 4.88–4.08 (m, 1H), 1.72–1.64 (m, 2H), 1.49–1.43 (m, 1H), 1.48 (d, *J* = 6.9 Hz, 3H), 1.43 (s, 9H), 0.95 (d, *J* = 6.4 Hz, 3H), 0.94 (d, *J* = 6.2 Hz, 3H); ¹³C NMR δ 171.4, 155.8, 143.1, 135.5, 128.3, 127.1, 125.9, 80.1, 52.9, 48.6, 40.6, 28.2, 24.7, 22.8, 22.1, 22.0. Anal. Calcd for C₁₉H₃₀N₂O₃: C, 68.23; H, 9.04; N, 8.38. Found: C, 68.40; H, 9.42; N, 8.40.

tert-Butyl N-((1S)-1-benzyl-2-oxo-2-[(1R)-1-phenylethyl]amino)ethyl]carbamate (6e). Colorless needles (95%), mp 127–128 °C (lit.¹⁷ no melting point given); ¹H NMR δ 7.32–7.15 (m, 10H), 5.91 (brs, 1H), 5.10 (brs, 1H), 5.02–4.90 (m, 1H), 4.31–4.25 (m, 1H), 3.12 (dd, *J* = 6.0, 13.6 Hz, 1H), 2.99 (dd, *J* = 13.5, 8.0 Hz, 1H), 1.41 (s, 9H), 1.29 (d, *J* = 6.7 Hz, 3H); ¹³C NMR δ 170.3, 152.6, 142.8, 129.6, 129.5, 128.9, 128.8, 127.5, 127.1, 126.2, 68.0, 56.2, 49.0, 38.9, 28.5, 21.9. Anal. Calcd for C₂₂H₂₈N₂O₃: C, 71.71; H, 7.66; N, 7.60. Found: C, 71.36; H, 7.87; N, 7.96.

References

[§] Current address: Neurogen Corporation, 35 Northeast Industrial Road, Branford, CT 06405.

- (a) Quibell, M.; Packman, L. C.; Johnson, T. *J. Chem. Soc., Perkin Trans. I* **1996**, 1219. (b) Davies, M.; Bradley, M. *Tetrahedron* **1999**, *55*, 4733. (c) Hamuro, Y.; Marshall, W. J.; Scialdone, M. A. *J. Comb. Chem.* **1999**, *1*, 163. (d) Lee, Y.; Silverman, R. B. *J. Am. Chem. Soc.* **1999**, *121*, 8407. (e) Yamada, M.; Miyajima, T.; Horikawa, H. *Tetrahedron Lett.* **1998**, *39*, 289. (f) Drouillat, B.; Kellam, B.; Dekany, G.; Starr, M. S.; Toth, I. *Bioorg. & Med. Chem. Lett.* **1997**, *7*, 2247. (g) Tetzlaff, C. N.; Schwoppe, I.; Bleczinski, C. F.; Steinberg, J. A.; Richert, C. *Tetrahedron Lett.* **1998**, *39*, 4215. (h) Swayze, E. E. *Tetrahedron Lett.* **1997**, *38*, 8465. (i) Wang, W.; McMurray, J. S. *Tetrahedron Lett.* **1999**, *40*, 2501; (j) Hall, B. J.; Sutherland, J. D. *Tetrahedron Lett.* **1998**, *39*, 6593. (k) Albericio, F.; Bailén, M. A.; Chinchilla, R.; Dodsworth, D. J.; Nájera, C. *Tetrahedron* **2001**, *57*, 9607.
- Jones, J. *Amino Acid and Peptide Synthesis*; Davies, S. G., Ed.; Oxford Science Publication, Oxford University Press: New York, 1992.
- Corbett, A. D.; Gleason, J. L. *Tetrahedron Lett.* **2002**, *43*, 1369.
- Bailén, M. A.; Chinchilla, R.; Dodsworth, D. J.; Nájera, C. *Tetrahedron Lett.* **2002**, *43*, 1661.
- Fischer, E.; Otto, E. *Ber.* **1903**, *36*, 2106.
- Carpino, L. A.; Cohen, B. J.; Stephens, Jr., K. E.; Sadat-Aalace, Y.; Tien, J.-H.; Langridge, D. C. *J. Org. Chem.* **1986**, *51*, 3732.
- Carpino, L. A.; Mansour, E.-S. M. E.; Sadat-Aalae, D. *J. Org. Chem.* **1991**, *56*, 2611.

8. (a) Carpino, L. A.; Sadat-Aalae, D.; Chao, H. G.; DeSelms, R. H. *J. Am. Chem. Soc.* **1990**, *112*, 9651. (b) Bertho, J.-N.; Loffet, A.; Pinel, C.; Reuther, F.; Sennyey, G. *Tetrahedron Lett.* **1991**, *32*, 1303.
9. Staab, H. A.; Bauer, H.; Schneider, K. M. *Azolides in Organic Synthesis and Biochemistry*; Wiley-VCH: Germany, 1998; pp 129-205
10. Katritzky, A. R.; He, H.-Y.; Suzuki, K. *J. Org. Chem.* **2000**, *65*, 8210.
11. Katritzky, A. R.; Wang, M.; Zhang, S. *ARKIVOC* **2001**, (ix), 19.
12. Parker, D. *Chem. Rev.* **1991**, *91*, 1441.
13. Landi, Jr., J. J.; Brinkman, H. R. *Synthesis* **1992**, 1093.
14. Bieth, J.; Dimicoli, J. L.; Wermuth, C. G. *Ger. Offen.* 2 806 833; *Chem. Abstr.* **1979**, *90*, 72447g.
15. Costello, G. F.; James, R.; Shaw, J. S.; Slater, A. M.; Stutchbury, N. C. J. *J. Med. Chem.* **1991**, *34*, 181.
16. Afzali-Ardakani, A.; Rapoport, H. *J. Org. Chem.* **1980**, *45*, 4817.
17. Lawrence, R. M.; Biller, S. A.; Fryszman, O. M.; Poss, M. A. *Synthesis* **1997**, 553.